 NEW HAVEN, Conn., June 9, 2021 PRNewswire -- Trevi Therapeutics, Inc. Nasdaq: TRVI, a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy HaduvioTM nalbuphine ER to treat serious neurologically mediated conditions, today announced that Jennifer Good, President and CEO, has been selected to deliver a company presentation at 2021 BIO Digital. 